Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-05-05
2010-10-26
Audet, Maury (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C424S001690, C514S002600, C530S330000
Reexamination Certificate
active
07820621
ABSTRACT:
The present invention provides compounds for targeting endothelial cells, tumor cells or other cells that express the NP-1 receptor, compositions containing the same and methods for their use. Additionally, the present invention includes diagnostic, therapeutic and radiotherapeutic compositions useful for visualization, therapy or radiotherapy.
REFERENCES:
patent: 5659041 (1997-08-01), Pollak et al.
patent: 5789555 (1998-08-01), Pollak
patent: 5821330 (1998-10-01), Itaya et al.
patent: 5855866 (1999-01-01), Thorpe et al.
patent: 6051230 (2000-04-01), Thorpe et al.
patent: 6252664 (2001-06-01), Garbera-Guillem
patent: 6261535 (2001-07-01), Thorpe et al.
patent: 6261537 (2001-07-01), Klaveness et al.
patent: 6264917 (2001-07-01), Klaveness et al.
patent: 6333110 (2001-12-01), Garbera-Guillem
patent: 6521211 (2003-02-01), Unger et al.
patent: 6777534 (2004-08-01), Klagsbrun et al.
patent: 6800273 (2004-10-01), Rajopadhye et al.
patent: 7052705 (2006-05-01), Rosenbaum et al.
patent: 7109167 (2006-09-01), Von Wronski et al.
patent: 2002/0001566 (2002-01-01), Rajopadhye et al.
patent: 2003/0082103 (2003-05-01), Wartchow et al.
patent: 2003/0133972 (2003-07-01), Danthi et al.
patent: 0649857 (1995-04-01), None
patent: WO 94/10202 (1994-05-01), None
patent: 95/13832 (1995-05-01), None
patent: WO 96/40285 (1996-12-01), None
patent: WO 98/18498 (1998-05-01), None
patent: WO 98/18500 (1998-05-01), None
patent: WO 98/18501 (1998-05-01), None
patent: WO 98/47541 (1998-10-01), None
patent: WO 98/53857 (1998-12-01), None
patent: WO 99/13919 (1999-03-01), None
patent: WO 99/20312 (1999-04-01), None
patent: WO 99/29861 (1999-06-01), None
patent: WO 99/40947 (1999-08-01), None
patent: 99/51628 (1999-10-01), None
patent: WO 99/58612 (1999-11-01), None
patent: WO 01/42284 (2001-06-01), None
patent: WO 01/54723 (2001-08-01), None
patent: WO 01/62942 (2001-08-01), None
patent: WO 01/70945 (2001-09-01), None
patent: WO 01/83693 (2001-11-01), None
patent: 01/98294 (2001-12-01), None
patent: WO 01/97850 (2001-12-01), None
patent: WO 01/98094 (2001-12-01), None
patent: WO 02/07747 (2002-01-01), None
patent: WO 03/028643 (2003-04-01), None
patent: WO 03/029814 (2003-04-01), None
patent: WO 03/092737 (2003-11-01), None
patent: WO 03/094617 (2003-11-01), None
patent: WO 03/103581 (2003-12-01), None
Dunn-Dufault, “5, Convenient Preparation of No-Carried-Added-Technetium-99m”, Radiopharmaceuticals Using Solid-Phase Technology, 1999, pp. 832-837, vol. 10., XP002200847 Washington, US; abstract; figures 1,2.
Online Medical Dictionary. “Amino acid”. http://cancerweb.ncl.ac.uk/cgi-bin/omd?query=amino+acid. Nov. 19, 1997.
Online Medical Dictionary. “Analogue”. http://cancerweb.ncl.ac.uk/cgi-bin/omd?query=analogue. Jan. 10, 1998.
Dunn-Default et al. “Convenient Preparation of No-Carrier-Added Technetium-99m Radiopharmaceuticals Using Solid-Phase Technology” Bioconjugate Chemistry, vol. 10, 1999, pp. 832-837.
Goodbody et al. “A new Tc-99m labelled peptide inflammation imaging agent” European Journal of Nuclear Medicine, vol. 21, No. 8, Aug. 1, 1994, p. 790.
Iles et al. “A pilot phase II clinical study on imaging inflammatory lesions in patients with Crohn's disease using Tc-99m RP128” Journal of Nuclear Medicine, vol. 39, No. 5, May 1998, p. 271P.
Linder Karen E.
Marinelli Edmund R.
Nanjappan Palaniappa
Nunn Adrian D.
Pillai Radhakrishna K.
Audet Maury
Bracco International B.V.
Kramer Levin Naftalis & Frankel LLP
LandOfFree
Compounds for targeting endothelial cells, compositions... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compounds for targeting endothelial cells, compositions..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds for targeting endothelial cells, compositions... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4160091